Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sichuan Kelun-Biotech Biopharmaceutical is the lead sponsor of 42 current clinical trials in our China register. 30 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Sacituzumab tirumotecan, Cisplatin and Carboplatin. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

Recruiting3071%
Not yet open12%
Active, closed1126%

Trials by phase

Phase 21740%
Phase 11024%
Phase 31024%
Phase 1/2512%

Clinical trials sponsored by Sichuan Kelun-Biotech Biopharmaceutical

42 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
SKB445 for Injection in Solid Tumors NCT06826040 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-02	China
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer NCT07697586 · ClinicalTrials.gov ↗ · NSCLC Drugs: Sacituzumab tirumotecan, SKB118	Phase 2	Recruiting	2026-08	China
A Study of SKB315 in Patients With Advanced Solid Tumors NCT05367635 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: SKB315	Phase 1	Recruiting	2022-03	China
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer NCT07329322 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Osimertinib, Sacituzumab tirumotecan	Phase 2	Recruiting	2026-03	China
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities NCT07308106 · ClinicalTrials.gov ↗ · Non-small Lung Cancer	Phase 2	Recruiting	2026-04	China
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors NCT06726369 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2024-12	China
SKB565 for Injection in Advanced Solid Tumors NCT07545265 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	2026-08	China
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors NCT06725381 · ClinicalTrials.gov ↗ · Solid Malignancies Drug: SKB571	Phase 1	Recruiting	2024-12	China
SKB118 Injection in Advanced Solid Tumors NCT07586943 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Sacituzumab tirumotecan, SKB118	Phase 1/2	Recruiting	2026-06	China
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma NCT07324629 · ClinicalTrials.gov ↗ · Thymic Carcinoma Drug: Sacituzumab tirumotecan	Phase 2	Recruiting	2026-03	China
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors NCT06736327 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: SKB500	Phase 1	Recruiting	2024-12	China
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT07622186 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Furmonertinib	Phase 2	Recruiting	2026-07	China
SKB500 Combinations in Patients With Small Cell Lung Cancer NCT07296809 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	2026-01	China
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154 · ClinicalTrials.gov ↗ · HNSCC Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 2	Recruiting	2026-07	China
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06279364 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Capecitabine, Carboplatin, Eribulin	Phase 3	Recruiting	2024-02	China
A Study of SKB518 in Patients With Lung Cancer NCT07019675 · ClinicalTrials.gov ↗ · Lung Carcinoma	Phase 2	Recruiting	2025-08	China
A Phase II Study of SKB571 in Patients With Lung Cancer NCT07230405 · ClinicalTrials.gov ↗ · Lung Cancer (Non-Small Cell) Drug: SKB571	Phase 2	Recruiting	2026-01	China
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Recruiting	2025-07	China
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Recruiting	2023-10	China
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Cisplatin, Ivonescimab, SKB500	Phase 2	Recruiting	2026-08	China
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors NCT07448922 · ClinicalTrials.gov ↗ · Advanced Gynecological Malignancies	Phase 2	Recruiting	2026-04	China
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. NCT05351788 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Sacituzumab tirumotecan	Phase 2	Recruiting	2022-05	China
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants NCT07488065 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 1	Recruiting	2026-03	China
A Study of SKB571 in Participants With Gastrointestinal Tumors NCT07564466 · ClinicalTrials.gov ↗ · Gastrointestinal Tumors Drug: SKB571	Phase 2	Recruiting	2026-05	China
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer NCT07299825 · ClinicalTrials.gov ↗ · Her 2 Positive Breast Cancer	Phase 2	Recruiting	2024-09	China
A Study of SKB518 in Patients With Advanced Solid Tumors NCT06428331 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2024-07	China
SKB105 for Injection in Advanced Solid Tumors NCT07380386 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	2026-03	China
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma NCT07732023 · ClinicalTrials.gov ↗ · Asthma (Diagnosis)	Phase 1	Recruiting	2026-08	China
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases NCT07087197 · ClinicalTrials.gov ↗ · Metastatic Solid Tumors	Phase 1	Recruiting	2025-08	China
SKB103 for Injection in Advanced Solid Tumors NCT07459998 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	2026-04	China
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma NCT07609667 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma Drugs: Capecitabine, SKB315, Tislelizumab	Phase 2	Not yet open	2026-06	China
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients NCT05870319 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Pemetrexed	Phase 3	Active, closed	2023-06	China
A Study of KL590586 in Patients With Advanced Solid Tumors NCT05265091 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Active, closed	2021-09	China
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy NCT06968585 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Active, closed	2023-07	China
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06711900 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 3	Active, closed	2024-10	China
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT05294172 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Recurrent or Metastatic Drugs: Cisplatin, Gemcitabine, Tagitanlimab	Phase 3	Active, closed	2022-06	China
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC NCT07341100 · ClinicalTrials.gov ↗ · Ovarian Epithelial Cancer	Phase 2	Active, closed	2026-01	China
A Study of A166 in Patients With Advanced Solid Malignant Tumors NCT05311397 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Active, closed	2018-08	China
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06448312 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Pembrolizumab, Sacituzumab tirumotecan	Phase 3	Active, closed	2024-06	China
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06670196 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Osimertinib, Sacituzumab tirumotecan	Phase 3	Active, closed	2024-11	China
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer NCT05347134 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drug: Sacituzumab tirumotecan	Phase 3	Active, closed	2022-06	China
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors NCT05631262 · ClinicalTrials.gov ↗ · Selected Subjects With Advanced Solid Tumors	Phase 2	Active, closed	2022-11	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sichuan Kelun-Biotech Biopharmaceutical trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Sacituzumab tirumotecan11 Cisplatin7 Carboplatin6 SKB5715 Pembrolizumab4 Osimertinib3 Capecitabine2 Pemetrexed2 SKB1182 SKB3152 SKB5002 Tagitanlimab2 Tislelizumab2 Eribulin1 Furmonertinib1 Gemcitabine1 Ivonescimab1 Nab-paclitaxel1 Paclitaxel1

Conditions in Sichuan Kelun-Biotech Biopharmaceutical trials

28 conditions

Advanced Solid Tumors9 Non-Small Cell Lung Cancer5 Non-small Cell Lung Cancer2 Triple Negative Breast Cancer2 Metastatic Breast Cancer2 NSCLC1 Gastroesophageal Junction Adenocarcinoma1 Advanced Solid Tumor1 HER2-positive Breast Cancer1Non-small Lung Cancer1Solid Malignancies1Nasopharyngeal Carcinoma1Recurrent or Metastatic1Ovarian Epithelial Cancer1Breast Cancer1Thymic Carcinoma1Small Cell Lung Cancer1 HNSCC1Lung Carcinoma1Lung Cancer (Non-Small Cell)1 Esophageal Squamous Cell Carcinoma1Advanced Gynecological Malignancies1Atopic Dermatitis1 Gastrointestinal Tumors1

By trial register

Register	Trials	Recruiting
Clinical trials in China	42	30

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumors

Sponsor	Trials
Jiangsu HengRui Medicine	7
Suzhou Suncadia Biopharmaceuticals	7
Shanghai Hengrui Pharmaceutical	6
Bristol-Myers Squibb	5
MediLink Therapeutics (Suzhou)	5
Hangzhou Zhongmei Huadong Pharmaceutical	5
Hansoh BioMedical R&D Company	4
Bayer	3
Vividion Therapeutics	3
Multitude Therapeutics	3

Sponsors with the most current trials registered for this condition.

Questions about Sichuan Kelun-Biotech Biopharmaceutical trials

How many clinical trials does Sichuan Kelun-Biotech Biopharmaceutical sponsor?

Sichuan Kelun-Biotech Biopharmaceutical is the lead sponsor of 42 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sichuan Kelun-Biotech Biopharmaceutical trials recruiting?

Yes. 30 of its 42 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan Kelun-Biotech Biopharmaceutical testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Sacituzumab tirumotecan (11), Cisplatin (7), Carboplatin (6), SKB571 (5) and Pembrolizumab (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sichuan Kelun-Biotech Biopharmaceutical clinical trials